How Much Do GLP-1 Weight Loss Drugs Cost Employers?

Published on August 8, 2026 | Written by Alec Pow
This article was researched using 14 sources. See our methodology and corrections policy.

GLP-1 weight-loss drugs have become one of the biggest new pharmacy expenses facing U.S. employers. For a company paying the full Lilly Employer Connect medication amount, Zepbound is $449 per treated employee for each 28-day supply. That works out to about $5,837 per treated employee across 13 fill cycles, before pharmacy, program-administrator, or clinical-service fees.

The expense can move far above that level under a traditional pharmacy benefit. Employer-paid amounts depend on negotiated drug terms, rebates, employee cost sharing, the number of workers approved for treatment, and how long they continue filling prescriptions. At the corporate level, the numbers can become enormous. Bank of America disclosed in August 2026 that it spends more than $250 million a year on GLP-1 drugs from a health-care budget of roughly $2 billion.

The useful employer unit is annual spending per treated member, followed by total treated headcount. A plan covering 100 users faces a very different bill from one covering 1,000 users, even when the medication rate is identical. Persistence and access rules then change how many paid fills occur during the year.

TL;DR: GLP-1 weight-loss drugs can cost employers roughly $5,837 to nearly $8,000 per treated worker per year using current direct-employer and estimated net-payer benchmarks, and large employers can face multimillion-dollar or even nine-figure annual bills.

How Much Do GLP-1 Weight Loss Drugs Cost Employers?

• Direct employer Zepbound price $449 (at $30 per hour, earning that amount would take about 1.9 full-time workdays, before taxes) per 28-day supply through Lilly Employer Connect as of March 2026.
• 13-cycle Zepbound medication total about $5,837 per treated worker before added service fees.
• Estimated net payer price $6,829 per year for injectable semaglutide and $7,973 per year for tirzepatide in ICER’s December 2025 analysis.
• Bank of America example more than $250 million annually in GLP-1 spending from a health-care budget of roughly $2 billion.

What this is about

Employer-paid GLP-1 coverage is a pharmacy benefit for workers and dependents who meet the health plan’s eligibility rules and receive a prescription. Wegovy, Zepbound, Ozempic, and Mounjaro move through a chain that can involve the prescriber, pharmacy, health plan, pharmacy benefit manager, and drug manufacturer. The employer pays its share of approved claims rather than purchasing medication for every employee who might qualify for treatment.

This differs from direct-pay programs such as Ro weight-loss treatment or Found weight-loss treatment, where consumers may pay membership and medication charges themselves. It also differs from gastric bypass surgery, which carries hospital, surgeon, anesthesia, and follow-up charges. For an employer, the main financial issue is recurring pharmacy spending multiplied by the number of active users.

Bank of America’s $250 million GLP-1 bill

Bank of America gave employers a rare public example of what GLP-1 spending can look like inside a very large company. CEO Brian Moynihan said in August 2026 that the bank spends more than $250 million (about 4 thousand years of full-time work at $30 per hour) each year on GLP-1 drugs for employees, up from essentially nothing several years earlier, and that the expense comes from a company health-care budget of roughly $2 billion, according to the Bank of America disclosure. Dividing $250 million by $2 billion puts the disclosed GLP-1 amount at at least 12.5% of that health-care budget. The actual percentage is slightly higher because Moynihan described GLP-1 spending as more than $250 million.

The figure attracted attention because corporate benefit costs are seldom disclosed at the drug-class level. Bank of America’s number also shows why an inexpensive-looking per-member figure can become a large budget item once thousands of workers use treatment for repeated fill cycles. Moynihan has defended the spending as an investment in employee health, putting the bank on the opposite side of companies that have started removing obesity-drug coverage. That contrast has turned employer GLP-1 coverage from a pharmacy-management issue into a broader corporate benefits story.

What employers can pay

Lilly introduced a lower direct employer route in March 2026. Its Employer Connect launch states that Zepbound KwikPen is available at $449 (about 1.9 full-time workdays at $30 per hour) for each 28-day supply across doses through participating program administrators. The employer decides how much of that amount to subsidize for employees, and Lilly states that final employer expense can change with the pharmacy and program administrator selected. Thirteen 28-day supplies cover 364 days, so $449 multiplied by 13 produces $5,837 per treated member before added service charges. That changes the math. A direct employer arrangement can sit well below older branded-drug sticker prices.

Traditional pharmacy-benefit spending can still land higher. ICER’s December 2025 obesity evidence report estimated annual net payer prices of $6,829 for injectable semaglutide and $7,973 for tirzepatide after estimated concessions. Those are market estimates, not guaranteed employer contract rates. SHRM reported another employer-facing range in June 2026, stating that branded injectable GLP-1 drugs could run $1,000 to $1,500 per month before plan-specific adjustments, with employers potentially funding 70% to 100% of the expense in the SHRM employer cost report.

Company expense examples

The easiest way to see the employer exposure is to multiply a sourced per-member drug amount by treated headcount. The cases below are planning models, not claims about unnamed companies. The first uses Lilly’s $449 employer price across 13 fill cycles. The second uses ICER’s estimated $6,829 annual net payer amount for injectable semaglutide from its December 2025 final report. The third uses ICER’s $7,973 tirzepatide estimate. Each case assumes the stated number of treated members remains on therapy for the modeled period.

Employer case	Treated workers	Cost input	Annual medication expense
Direct Zepbound case	100	$5,837 per worker	$583,700
Semaglutide net-price case	500	$6,829 per worker	$3,414,500
Tirzepatide net-price case	1,000	$7,973 per worker	$7,973,000

The scale gets large fast. Five hundred treated workers at $6,829 each create $3,414,500 in annual medication expense, and 1,000 treated workers at $7,973 create $7,973,000. Employee contributions or stronger negotiated terms can reduce the employer share. Pharmacy fees, clinical programs, or weaker net pricing can push the employer’s expense in the opposite direction. These examples explain why benefits teams focus heavily on how many members qualify and how long they remain active users.

Hidden costs

The medication amount is not always the final company bill. Employer programs can add clinical consultations, eligibility verification, coaching, lab services, pharmacy processing, prior-authorization administration, and fees charged by a program administrator. Lilly’s employer platform says the final expense can change according to the pharmacy and independent administrator chosen, which means two employers using the same drug price can still end up with different program totals.

That eMed figure applies to its advertised health-system offer, not every employer program. PBMs and other obesity-care vendors may use different fee structures. Employers also need to examine how rebates are credited, whether administrative charges sit inside the pharmacy contract, and whether clinical services are billed separately. A medication-only quote can look lower than the final plan expense when those lines are omitted.

Worked employer budget

Consider a self-funded employer with 500 workers receiving injectable semaglutide for a full year. Using the cited ICER net payer estimate of $6,829 per treated member per year, the medication calculation is 500 multiplied by $6,829, producing $3,414,500 in annual drug expense. This is a budgeting example rather than a national employer benchmark, since a specific company’s PBM agreement, rebates, and employee contributions can produce a different paid amount.

• 500 treated workers
• Annual medication input per worker $6,829
• Medication total $3,414,500
• Illustrative eMed starting program fee for 500 enrolled employees $12,500 per month
• Twelve months of that program fee $150,000
• Combined modeled amount $3,564,500

The arithmetic adds $3,414,500 in modeled medication spending to $150,000 in program fees, producing $3,564,500. The example does not add an invented pharmacy fee, rebate, copay, or lab charge. Those figures need to come from the employer’s actual contracts. The exercise shows why quoting only the medication price can understate the amount a benefits department may need to place in its annual budget.

Utilization rules and persistence

Price per prescription matters, but user count and refill duration can have an equally large effect on company spending. EBRI’s October 2025 employer premium simulation varied drug expense, adherence, employee cost sharing, and eligibility criteria when modeling GLP-1 coverage. That structure mirrors the real budget problem. A company can negotiate a lower drug rate and still see spending rise if far more members qualify or remain on therapy for longer periods. Prior authorization, BMI thresholds, qualifying conditions, selected prescribers, and weight-management requirements can all change the number of paid claims.

Medical savings also operate on a different timetable from pharmacy spending. Aon’s January 2026 workforce GLP-1 analysis examined 192,000 GLP-1 users using commercial medical and pharmacy claims drawn from about 50 million covered lives. The analysis found improving medical cost growth for continuous users in the second year compared with matched non-users, but employers still carried the medication expense during treatment. A company should not budget as if later medical savings automatically cancel the near-term pharmacy claim because employee turnover, treatment duration, diagnoses, and adherence can change the financial result.

Who this cost makes sense for

Some employers are keeping broad GLP-1 coverage because they view obesity treatment as part of their health strategy. Others are reducing access because the pharmacy bill has grown faster than their benefits budget. Starbucks confirmed that its health plans will stop covering GLP-1 drugs prescribed for weight loss beginning in October 2026, according to Starbucks coverage reporting. PwC also ended weight-loss GLP-1 coverage in July 2026 except for certain medical uses such as diabetes, according to the PwC benefit change. Those decisions contrast directly with Bank of America’s willingness to keep paying a nine-figure annual GLP-1 bill.

The choice comes down to how much pharmacy exposure the employer can fund, how access is managed, and what the company expects the benefit to accomplish for its workforce. Employers with weak claims reporting can have trouble separating diabetes use from obesity treatment or spotting rapid growth in new starts. Companies with stronger utilization controls can set eligibility rules and monitor persistence before renewal decisions.

Makes sense if

• The company wants obesity treatment included in its pharmacy benefit.
• The plan can track GLP-1 claims by indication and refill history.
• The benefits budget can support recurring medication expense.
• Eligibility and authorization rules are defined before enrollment rises.

Doesn’t make sense if

• The company cannot absorb rapid growth in treated members.
• The plan cannot separate drug spending from vendor and administrative fees.
• The employer expects short-run medical savings to erase pharmacy claims.
• Renewal decisions are being made without usable utilization data.

What we verified

• Checked that 59% of the largest firms offering weight-loss GLP-1 coverage said use exceeded expectations and 66% reported a major effect on prescription spending in the KFF employer analysis.
• Confirmed that 67% of surveyed employers covered GLP-1 drugs for weight management in 2026 and only 72% of those expected to continue in 2027 in the Business Group survey.
• Cross-referenced that weight-loss GLP-1 drugs represented 11.4% of annual claims among corporate respondents in the IFEBP 2026 survey.
• Verified that 6% of large employers had dropped weight-loss GLP-1 coverage in 2026 and 27% had tightened or planned to tighten utilization controls through Mercer’s 2026 findings.

Article Highlights

• A current direct-employer Zepbound benchmark is $449 per 28-day supply.
• Thirteen fills at that price equal about $5,837 per treated worker per year.
• ICER estimated annual net payer amounts of $6,829 for injectable semaglutide and $7,973 for tirzepatide in late 2025.
• 500 semaglutide users at the cited ICER amount equal about $3.41 million per year before other plan charges.
• Bank of America says it spends more than $250 million annually on GLP-1 drugs.
• Headcount, refill persistence, eligibility rules, rebates, and vendor fees can move the employer total materially.

Answers to Common Questions

How much can one employee on a GLP-1 cost an employer?

A useful 2026 benchmark runs from about $5,837 per year using Lilly’s direct employer Zepbound price across 13 fill cycles to $7,973 per year using ICER’s estimated net payer amount for tirzepatide. Company contracts can produce different results.

How much could GLP-1 drugs cost a company with 500 treated workers?

Using ICER’s $6,829 annual semaglutide estimate, 500 treated workers equal $3,414,500 per year in modeled medication expense before vendor fees and company-specific pharmacy adjustments.

How much is Bank of America spending on GLP-1 drugs?

Bank of America disclosed spending of more than $250 million per year on GLP-1 medications in August 2026, compared with a health-care budget of roughly $2 billion.

Why are some employers ending weight-loss GLP-1 coverage?

Employers including Starbucks and PwC have restricted weight-loss coverage as pharmacy spending has risen. Other companies continue coverage but use eligibility checks, prior authorization, employee cost sharing, or direct manufacturer arrangements to control plan expense.